NCT Number: NCT04848337
Phase: Phase 2
Trial Summary: Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Michigan Rogel Cancer Center
Acronym: PLANE-PC
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives